ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums Drugs and Pharmaceuticals Ltd filed its quarterly shareholding pattern, noting the removal of two entities from the promoter group due to their legal dissolution.
Akums Drugs and Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The filing confirms adherence to SEBI listing and disclosure regulations.
Akums Drugs and Pharmaceuticals received a voluntary ESG rating of 63 from NSE Sustainability for FY 2024-25. The rating was assigned using publicly available information.
Akums Drugs and Pharmaceuticals Limited submitted a compliance certificate for the quarter ended March 31, 2026. The filing confirms the processing of dematerialisation requests by its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, within prescribed timelines.